2-Ethyl-5-methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester | 110886-26-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 2-Ethyl-5-methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester
• 英文别名: Ethyl 2-ethyl-5-methylpyrazolo[1,5-a]pyridine-3-carboxylate
• CAS: 110886-26-5
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.282
• InChiKey: XMDVGPDCMDLIKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Ethyl-5-methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester 在 platinum(IV) oxide 作用下， 以 乙醇 、 水 为溶剂， 以64 %的产率得到
  参考文献：
  名称：

  [EN] IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
  [FR] AMIDES D'IMIDAZOPYRIDINE ET COMPOSÉS APPARENTÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'INFECTIONS BACTÉRIENNES

  摘要：

  The present invention relates to the following compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis (e.g. in combination).

  公开号：

  WO2023073090A1
• 作为产物：
  描述：

  1-[1-Ethoxycarbonylmethylsulfanyl-prop-(Z)-ylideneamino]-4-methyl-pyridinium; bromide 在 potassium carbonate 作用下， 以 氯仿 为溶剂， 反应 24.0h， 以85%的产率得到2-Ethyl-5-methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Kakehi, Akikazu; Ito, Suketaka; Nagata, Kenji, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 1, p. 156 - 169

  摘要：

  DOI：

文献信息

• KAKEHI AKIKAZU; ITO SUKETAKA; NAGATA KENJI; KINOSHITA NAOSUMI; KAKINUMA N+, CHEM. AND PHARM. BULL., 35,(1987) N 1, 156-169
  作者：KAKEHI AKIKAZU、 ITO SUKETAKA、 NAGATA KENJI、 KINOSHITA NAOSUMI、 KAKINUMA N+

  DOI：——

  日期：——
• PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF
  申请人：GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES

  公开号：US20170313697A1

  公开（公告）日：2017-11-02

  Disclosed in the disclosure are a pyrazolo[1,5-a]pyrideine compound with structural features as shown in formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (MIC) of the compounds is lower than 0.1 μg/mL and partially achieves 0.01 μg/mL, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (MDR-TB) strains. In an in vivo experiment, the pyrazolo[1,5-a]pyrideine compounds of the present disclosure can effectively scavenge the infectious dose of H37Ra in a mouse body at 20 mg/kg/d does, thereby being a new type of antituberculosis compound.
• WO2024089170A1
  申请人：——

  公开号：——

  公开（公告）日：——
• Kakehi, Akikazu; Ito, Suketaka; Nagata, Kenji, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 1, p. 156 - 169
  作者：Kakehi, Akikazu、Ito, Suketaka、Nagata, Kenji、Kinoshita, Naosumi、Kakinuma, Noboru

  DOI：——

  日期：——
• [EN] IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] AMIDES D'IMIDAZOPYRIDINE ET COMPOSÉS APPARENTÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：[en]JANSSEN SCIENCES IRELAND UNLIMITED COMPANY

  公开号：WO2023073090A1

  公开（公告）日：2023-05-04

  The present invention relates to the following compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis (e.g. in combination).